Accelerate Gross Profit Margin from 2010 to 2024

AXDX Stock  USD 1.70  0.13  8.28%   
Accelerate Diagnostics Gross Profit Margin yearly trend continues to be fairly stable with very little volatility. Gross Profit Margin will likely drop to 0.20 in 2024. During the period from 2010 to 2024, Accelerate Diagnostics Gross Profit Margin regression line of annual values had significance of  0.000012 and arithmetic mean of  0.54. View All Fundamentals
 
Gross Profit Margin  
First Reported
2010-12-31
Previous Quarter
0.21146032
Current Value
0.2
Quarterly Volatility
0.28086535
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Accelerate Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Accelerate Diagnostics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.4 M, Interest Expense of 8.1 M or Selling General Administrative of 35.9 M, as well as many indicators such as Price To Sales Ratio of 3.85, Dividend Yield of 2.0E-4 or Days Sales Outstanding of 75.39. Accelerate financial statements analysis is a perfect complement when working with Accelerate Diagnostics Valuation or Volatility modules.
  
Check out the analysis of Accelerate Diagnostics Correlation against competitors.
For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.

Latest Accelerate Diagnostics' Gross Profit Margin Growth Pattern

Below is the plot of the Gross Profit Margin of Accelerate Diagnostics over the last few years. It is Accelerate Diagnostics' Gross Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Accelerate Diagnostics' overall financial position and show how it may be relating to other accounts over time.
Gross Profit Margin10 Years Trend
Slightly volatile
   Gross Profit Margin   
       Timeline  

Accelerate Gross Profit Margin Regression Statistics

Arithmetic Mean0.54
Coefficient Of Variation51.84
Mean Deviation0.25
Median0.76
Standard Deviation0.28
Sample Variance0.08
Range0.8895
R-Value(0.88)
Mean Square Error0.02
R-Squared0.78
Significance0.000012
Slope(0.06)
Total Sum of Squares1.10

Accelerate Gross Profit Margin History

2024 0.2
2023 0.21
2022 0.26
2021 -0.0323
2020 0.4
2019 0.47
2018 0.44

About Accelerate Diagnostics Financial Statements

Accelerate Diagnostics investors use historical fundamental indicators, such as Accelerate Diagnostics' Gross Profit Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Accelerate Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Gross Profit Margin 0.21  0.20 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Accelerate Stock Analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.